Overview

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Status:
Enrolling by invitation

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

Prospective clinical trial investigating combined, dual 18F-FDG PET/CT and 64Cu-DOTATATE PET/CT imaging of patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN)

Phase:

Phase 2

Details

Lead Sponsor:

Rigshospitalet, Denmark

Treatments:

Fluorodeoxyglucose F18